FLJ10540 is associated with tumor progression in nasopharyngeal carcinomas and contributes to nasopharyngeal cell proliferation, and metastasis via osteopontin/CD44 pathway

Table 3 Disease-specific survival by Cox regression analyses between the subgroups of various clincopathological parameters

Parameters	No	No of events	HR (95% CI ^a )	p- value^b
Age (years)			1.695 (0.743-3.875)	0.211
<50	24	8
≥ 50	39	19
Gender			0.596 (0.225-1.575)	0.297
Male	47	22
Female	16	5
Histology			0.930 (0.431-.006)	0.854
WHO type II	37	16
WHO type III	26	11
Primary tumor (T)			5.091 (2.350-11.030)	<0.001
T1-T2	44	12
T3-T4	19	15
Nodal status (N)			2.780 (1.302-5.934)	0.009
N0-N1	41	13
N2-N3	22	14
AJCC staging			4.464 (1.879-10.607)	0.001
Stage I-II	31	7
Stage III-IV	32	20
FLJ10540			4.741 (2.177-10.326)	<0.001
Low expression	42	11
High-expression	21	16
Osteopontin			5.012 (2.315-10.850)	<0.001
Low expression	47	14
High-expression	16	13

Abbreviations: HR Hazard Ratio, WHO World Healthy Organization; AJCC American Joint Committee on Cancer.
^a 95% Wald Confidence Limits.
^b Associations determined by Cox regression analyses. Statistically significant (p < 0.05).

ISSN: 1479-5876